SANDOZ has announced that Methylphenidate Sandoz XR (methylphenidate hydrochloride) has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of ADHD.
The central nervous system stimulant is a modified-release formulation of methylphenidate bioequivalent to Concerta (Janssen-Cilag), and is available in 18mg, 27mg, 36mg and 54mg tablets.
The number of Australians using ADHD medication has increased eleven-fold in the past 10 years, and with ongoing global shortages of methylphenidate, the listing supports improved access by providing an additional supply option for Australians living with ADHD.
Stock is expected to become available to wholesalers throughout November.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Nov 25
